Evaluation of a Pharmacist-Managed Antidiabetic Deprescribing Program in an Integrated Health Care System

Abstract

BACKGROUND: In the elderly, use of medications may increase the propensity for adverse drug events due to alterations in pharmacokinetic and pharmacodynamic profiles from normal aging processes. Deprescribing is the planned and supervised process of dose reduction or discontinuation of medications that may lead to harm or are no longer beneficial. While there are studies detailing strategies to deprescribe medications such as benzodiazepines and antipsychotics in nursing homes or for patients with dementia, there is a lack of guidance to safely deprescribe chronic medications, such as antidiabetics, for older patients in the community setting. OBJECTIVE: To evaluate the risk of hypoglycemia and other outcomes of pharmacist-managed deprescribing on selected antidiabetic medications under the guidance of a standardized program compared with usual care within an integrated health care system. METHODS: This was a retrospective propensity score-matched cohort study. The pharmacist-managed deprescribing group included patients who were enrolled in the deprescribing program between July 1, 2016, and June 30, 2017. The usual care group included eligible patients who did not receive the deprescribing intervention and were matched to the deprescribing group using propensity score matching (PSM). Baseline demographics and clinical variables were used for matching. Patients were followed for 6 months or the end of membership or death, whichever occurred first. Primary outcome was the risk of hypoglycemia. Secondary outcomes included risk of hyperglycemia, proportion of patients at goal (A1c), change in A1c, change in monthly antidiabetic drug cost, and all-cause mortality. Outcomes were analyzed using descriptive statistics and multivariant regression or Cox proportional hazard models when appropriate. RESULTS: After PSM, 685 patients in the deprescribing group and 2,055 patients in the usual care group were similar in age, gender, weight, and comorbidity burden (mean [SD] age 82.4 [5.4] years, 48% female, mean [SD] weight 81.7 [19.2] kg, mean [SD] Charlson Comorbidity Index score 3.2 [1 .6]). Compared with the usual care group, the deprescribing group had a lower risk of hypoglycemia (1.5% vs. 3.1%, P < 0.02; adjusted odds ratio 0.42, P < 0.01). As for the secondary outcomes, the deprescribing group had a greater change (SD) in A1c (0.3 [0.6] vs. 0.2 [0.7] P < 0.01) and lower all-cause mortality (2.3% vs 5.6%, P < 0.01; adjusted hazard ratio 0.35, P < 0.01). There were no differences observed in the risk of hyperglycemia, proportion of patients at goal A1c < 7%, and change in monthly antidiabetic drug costs between the 2 groups. CONCLUSIONS: There are currently no studies to our knowledge that evaluate the outcomes of a pharmacist-managed deprescribing program targeting antidiabetic medications. The results of our study showed that deprescribing of selected antidiabetics reduced the risk of hypoglycemia and may have mortality benefit in elderly patients with well-controlled type 2 diabetes, who are taking medications that c...

Understanding the rise of cardiometabolic diseases in low- and middle-income countries

“…[163][164][165][166][167][168][169] Different projects have been working towards improving the health system, at all levels (primary care, hospitals or specialized institutes) and working with all stakeholders (health workers, managers, regional health directors) to improve access to care, increase availability and affordability of medicines, improve coordination of care or improve patient satisfaction. [170][171][172][173] Given the comorbidity between mental health and cardiometabolic conditions, some projects have promoted the opportunistic screening of mental health disorders in this group of patients and their referral using existing resources. 174 Other ongoing initiatives are using mHealth technologies to treat mild to moderate depressive symptoms among patients with cardiometabolic conditions.…”

How to implement deprescribing into clinical practice

“…Education can include academic detailing (one-on-one) and/or deprescribing workshops. 63,64 Although there is no evidence to suggest the value and • Antidiabetics (especially shorter-acting insulin) [21][22][23] • Antihypertensives [24][25][26][27] • Antipsychotics [28][29] • Benzodiazepines and nonbenzodiazepine sleep medications [30][31] • Opioids 36 No further perceived benefit: Medications that do not carry a current, appropriate indication or are part of a prescribing cascade or scenarios where preventive medications are unlikely to confer any patientimportant benefits over the patient's remaining lifespan after a risk & benefit evaluation 6…”

A qualitative study on the development of pharmacist‐managed clinics in Taiwan

“…Pharmacist‐managed clinics (PMCs) provide outpatient services such as medication therapy management (MTM), disease management and patient education 1 . Previous studies have shown that implementing MTM has a significant impact on enhancing medication adherence, improving clinical outcomes 2–9 and achieving cost‐effectiveness 10–14 …”